Market Research Report
Global Market for Regenerative Medicine (RM), 2019
|Published by||BIOINFORMANT WORLDWIDE, LLC||Product code||869663|
|Published||Content info||390 Pages
Delivery time: 1-2 business days
|Global Market for Regenerative Medicine (RM), 2019|
|Published: June 20, 2019||Content info: 390 Pages||
The Regenerative Medicine (RM) Industry has been rapidly expanding in recent years, making it a high-value, fast-growth market. Key drivers for the market include high rates of clinical trials, accelerated pathways for product approvals, new technologies to support cell and gene therapy manufacturing, and the potential for cell therapies to revolutionize healthcare.
There are now accelerated pathways for advanced therapy medicinal products (ATMPs) in several countries worldwide, including the U.S., Japan, and South Korea. Legislation took effect in Japan in late 2014, in South Korea in 2016, and in the United States in 2017. Additionally, the EU has a program for product acceleration - the Adaptive Pathways. These historic events demonstrate to investors, the public, and funding providers alike that regenerative medicine is a sector that has emerged, no longer one that is evolving in the future.
“Big Pharma” is also demonstrating snowballing interest in regenerative medicine. At its core, this is a strategic way for pharmaceutical companies to diversity their product development pipeline. Much of this interest has been driven by progress with immunotherapy treatments, such as CAR-T cell therapies, most notably, Kymriah and Yescarta. After attaining FDA approvals, these two products achieved historic approvals across varied geographic markets, providing hope to millions of cancer patients worldwide.
The Regenerative Medicine (RM) Industry also saw venture capital investment expand from a mere $200 million in 2010 to a stunning $14.6 billion in 2018. This upsurge in venture capital investment represents growth of 7,300% over an eight-year period. Aggressive construction of cell and gene therapy manufacturing facilities is also being undertaken by biotech companies seeking their own production capabilities, as well as by CDMOs planning to serve third-party clients from across the RM sector. With more than 900+ brave companies composing the marketplace, regenerative medicine advances are truly disrupting healthcare.
The Regenerative Medicine (RM) Industry includes companies that are developing:
As the first and only market research firm to specialize in the stem cell industry, BioInformant has an exceptional and unique understanding of the Regenerative Medicine (RM) Industry. Founded in 2006, BioInformant has collected over 13 years of historical data on the RM industry, providing it with a robust historical database of data on which to make future market projections. Headquartered in Washington, DC, BioInformant is strategically positioned near industry lawmakers, the National Institutes of Health (N.I.H.), the U.S. FDA, and the Maryland Biotech Corridor, among other critical resources.
In addition to leveraging an experienced team of analysts, this experience provides BioInformant with access to Key Opinion Leaders (KOLs) from across the RM sector, including dozens of executives who were interviewed for this report. To date, BioInformant has interviewed leadership from FUJIFILM, Pluristem Therapeutics, Cynata Therapeutics, RooserBio, Celularity, Hemostemix, Glycostem, Accellta, ORIG3N, Gamida Cell, Nohla Therapeutics, Fortuna Fix, Avery Therapeutics, Stem Cell Medicine Ltd., Minerva Biotechnologies, Celyad, Universal Cells, Rhemastem, and hundreds of others. With research cited by major news outlets that include the Wall Street Journal, Nature Biotechnology, Xconomy, and Vogue Magazine, BioInformant serves Fortune 500 leaders that include GE Healthcare, Pfizer, and Goldman Sachs.
Claim this global strategic report to learn: